Resources

BIA responds to MHRA's consultation on proposals for a new regulatory framework for rare disease therapies.

BIA responds to MHRA's consultation on expanding the definition of gene therapy to make the ATMP framework more future proof.

BIA has set out its position on mandatory patent description adaptation, warning that it could introduce unnecessary costs and risks for research-intensive life sciences innovators.

The BIA and ABPI have jointly responded to Department for Business and Trade consultation on the British Industrial Competitiveness Scheme: consultation on scheme eligibility and approach.

BIA submitted our response to a Science, Innovation and Technology Committee inquiry into life sciences investment.

The BIA has submitted its representation to HM Treasury for the Autumn Budget 2025.

We highlighted that the medicines supply chain is inherently global and the UK is highly reliant on overseas production; both of active pharmaceutical ingredients, excipients and other components, and more...

The BIA submitted our response to a Business and Trade Committee inquiry on UK trade with the US, India, and EU.

The MHRA has published a draft guideline on the use of external control arms (ECAs) based on real-world data (RWD) to support regulatory decisions. The consultation on the draft guideline closed on 14 July 2025.

BIA has responded to a HMRC consultation on R&D tax relief advance clearances, supporting government's aim to reduce error and fraud, increasing certainty for R&D tax relief claimants.

Our response to the Government’s consultation highlights the value of secure health data access for biotechs, the risks of uncontrolled broker use, and more.

BIA has responded to the call for evidence, highlighting the urgent need to close the scale-up funding gap and calling for pension fund reform to keep innovation and economic growth in the UK.

BIA has responded to the DBT's consultation on potential UK tariffs in response to US measures, urging to protect life sciences supply chains, innovation, and patient access.

Our response supported stronger HMRC powers to reduce fraud in the R&D tax relief system while protecting legitimate claims that drive innovation and economic growth.

BIA welcomes this call for evidence, as, while not currently a focus of the NWF, the life sciences could play an essential role in ensuring the fund achieves its objectives.

We've responded to the joint Intellectual Property Office (IPO), Department for Science, Innovation and Technology (DSIT) and Department for Culture, Media, and Sport (DCMS) consultation on Copyright and Artificial Intelligence (AI).